Vimarsana
Biggest News Aggregation in the World

Page 2 - Immunology Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunology Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunology Development Today - Breaking & Trending Today

Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study - Vimarsana News

Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study

Results show 26 weeks of treatment with twice-daily 60 mg dose of BMS-986278 resulted in a 69% relative reduction in the rate of decline in percent predicted forced vital capacity versus...

Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study - Bristol-Myers Squibb (NYSE:BMY) - Vimarsana News

Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study - Bristol-Myers Squibb (NYSE:BMY)

Results show 26 weeks of treatment with twice-daily 60 mg dose of BMS-986278 resulted in a 69% relative reduction in the rate of decline in percent predicted forced vital capacity versus placebo Treatment effect was

Nimbus Therapeutics Appoints Nathalie Franchimont, M.D., Ph.D., as Chief Medical Officer - Vimarsana News

Nimbus Therapeutics Appoints Nathalie Franchimont, M.D., Ph.D., as Chief Medical Officer

Nimbus Therapeutics Appoints Nathalie Franchimont, M.D., Ph.D., as Chief Medical Officer - read this article along with other careers information, tips and advice on BioSpace